NOVA1

Across TCGA cell cohorts, NOVA1 mutation is significantly associated with the drug of many other genes, with 21 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible NOVA1-associated genes across cancer lineages are Trametinib, LCL161, and GSK2801. Each is linked with NOVA1 in more than 1 cancer types. Because this analysis shows association rather than direction, both NOVA1-to-partner and partner-to-NOVA1 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, Trametinib grouped by NOVA1-low versus NOVA1-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (NOVA1→partner) and Y-score (partner→NOVA1) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Trametinib →	-0.666	-2.745	.034	.047	3	1
LARGE_INTESTINE	LCL161 →	+0.433	+2.868	.004	.022	3	1
LARGE_INTESTINE	GSK2801 →	+0.425	+2.900	.004	.015	3	1
LARGE_INTESTINE	123829 →	+0.619	+2.871	.024	.021	3	1
LARGE_INTESTINE	Venotoclax →	+0.154	+2.944	.041	.018	2	2
LARGE_INTESTINE	Nilotinib →	+0.506	+2.906	.018	.033	2	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 21 associations by consensus.

Trametinib by NOVA1 expression — LARGE_INTESTINE

Explore this box plot interactively →